Web Analytics
KMDA (NASDAQ) Stock Analysis | KAMADA – Deepscope
MARKET

Select Market Data Region

KMDA — KAMADA (Healthcare >> Drug Manufacturers - Specialty & Generic)

KMDA FAQ

What is KMDA's P/E ratio?

KAMADA (KMDA) currently trades at a P/E ratio of 20.95.

What is KMDA's ROE?

KAMADA reports a Return on Equity (ROE) of 7.85%.

What is KMDA's dividend yield?

KAMADA offers a dividend yield of 3.39%.

What is KMDA's Deepscope Quality Score?

Deepscope rates KMDA's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy KMDA?

Deepscope's AI Timing Score for KMDA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does KMDA belong to?

KAMADA is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.

Stock Check   *Daily update data at 9:30 AM*
(Price: 2026-06-05 | FS: 2026-03-31)

USD 7.17
-0.21 (-2.85%) Day Change
20.95
P/E
0.01
D/E
7.9%
ROE
5.3%
ROA
3.39%
Div Yield
-0.21
PEG
USD 7.17
Price
-0.21 (-2.85%)
Day Change
NEWS SCORE: 92

KMDA, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...

46

QUALITY

Signal
UNDERPERFORM
Signal Description
Company financial health is Not Good
Reason
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors 44%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 92
  Magic Formula Rank by ROA
1525
  Magic Formula Rank by ROE
1525
  Magic Formula Rank by ROIC
1493
  Price 7.17
  PBV / Sector
1.64 / 2.76
  Earning Per Share 0.34
  PE / Sector
20.95 / 23.64
  PEG or PE/Growth / Sector
-0.21 / 0.13
  Average 1M Daily Value
0.47 M
GREAT
  Average 1W Daily Value
0.38 M
GREAT
Timing Factors 28%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
Financial Health 45%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
Ability to Make Profit 60%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
11.21 / 15.98
  NPM Average (%) / Sector
7.08 / -16.38
  NPM Change Average (%) / Sector
-86.15 / 113.39
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
5.32 / 8.16
  ROA Average (%) / Sector
3.23 / 2.38
  ROA Change Average (%) / Sector
-80.20 / 108.63
  ROE (%) / Sector
7.85 / -0.19
  ROE Average (%) / Sector
4.60 / 7.40
  ROE Change Average (%) / Sector
-63.50 / 371.95
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
Return to Investors 62%
X
  Dividend (%) / Sector
3.39 / 0.53
GOOD
  Dividend Average (%) / Sector
3.15 / 3.08
  Dividend Change Average (%) / Sector
16.15 / 14.88
GOOD
Registration Details
X
  Analyze Date 2026-06-06 09:08:48
  Symbol KMDA
  Name KAMADA
  Sector Healthcare >> Drug Manufacturers - Specialty & Generic
  Market NASDAQ
  Listed Shares 57.69 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 426.68 / 9,835.56
News, Concensus, ...
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: 2 Holzman Street, Rehovot, Israel, 7670402

Phone: 972 8 940 6472

Website: https://www.kamada.com

Employees: 462

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic

KMDA (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
KMDA
KMDA
USD 7.17 (-2.85%)
+ Watch + Port Chart